GlassScriptPhysician profile
Caroline Arceri
NPI 1598281040
$1,051.64
in general payments reported to CMS, 2019-2025
12 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.19 · 2023: $705 · 2024: $15.35 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $250.21 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $169.71 | 2023 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $158.58 | 2023 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Corium, LLC | $114.02 | 2023 | Azstarys |
| Neurocrine Biosciences, INC. | $99.45 | 2022-2023 | Ingrezza |
| Lundbeck LLC | $54.83 | 2023 | Abilify Maintena |
| Alkermes, INC. | $52.20 | 2023 | Aristada, Lybalvi |
| Abbvie INC. | $43.60 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $43.51 | 2023 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $32.81 | 2023-2024 | Invega Trinza, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $16.90 | 2023 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $15.82 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Arceri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.